Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
neuroendocrine tumor 2 endocrinologydiseases
carcinoid 8 endocrinologydiseases
everolimus 12 endocrinologydiseasesdrugs
hyperglycemia 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
everolimus 40 Title: BMC CancerEfficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature
everolimus 652 established.Case presentationWe describe the case of a 47-year-old man with end-stage renal disease who received everolimus plus Lanreotide for 9 months for the management of metastatic atypical bronchial carcinoid.ConclusionsEverolimus
everolimus 1059 reductions and is overall well tolerated in hemodialysis patients.BackgroundIn two phase III trials everolimus has been shown to be active against neuroendocrine tumors (NETs) arising from the lung [[1], [2]]. Its
everolimus 1386 describe the case of a hemodialysis patient with metastatic atypical bronchial carcinoid treated with everolimus .Case presentationIn February 2011, a 47-year-old white male patient underwent right lung lobectomy for
everolimus 2020 was initiated and continued for 1 year. In March 2014 further disease progression was noted and oral everolimus was initiated at a dose of 10 mg/day, then reduced to 5 mg/day 1 month later due to persistent grade
everolimus 3605 the first report of a hemodialysis patient with metastatic atypical bronchial carcinoid treated with everolimus . In the one case of a hemodialysis patient with metastatic ileal well differentiated NET (G1) described
everolimus 3827 disease stabilization was achieved without any adverse effects [[7]].Clinical trials investigating everolimus activity have excluded ESRD patients because the condition is thought to alter drug pharmacokinetics.
everolimus 4160 toxicities [[8]], or it may be more rapid and thus reduce drug efficacy. Recent reports have documented that everolimus pharmacokinetics is not altered by hemodialysis in patients with metastatic renal cell cancer [[9]–[13]],
everolimus 4325 patients with metastatic renal cell cancer [[9]–[13]], probably owing to the absence of diffusion of everolimus through commonly used dialysis membranes and in the dialysate fluid (Table 1). Another explanation
everolimus 4478 and in the dialysate fluid (Table 1). Another explanation for the unchanged tolerability profile of everolimus in patients with renal insufficiency is that the drug is predominantly metabolized by the liver and
everolimus 5775 25% of cases [[15]]. In these young patients, pancreatic NETs occurrence is frequent. Treatment with everolimus may be considered safe in this patient setting. Everolimus therapy is feasible in hemodialysis patients
everolimus 6080 similar to those reported in patients with normal renal function. To confirm the clinical features of everolimus in NET patients undergoing hemodialysis, data collection from single case or case series is highly envisioned.
Select Disease Character Offset Disease Term Instance
carcinoid 122 CancerEfficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid : case report and literature reviewM. P. BrizziA. La SalviaM. TampelliniC. SonettoM. VolanteG. V. ScagliottiPublication
carcinoid 745 received everolimus plus Lanreotide for 9 months for the management of metastatic atypical bronchial carcinoid .ConclusionsEverolimus is a treatment option for hemodialysis patients with metastatic atypical bronchial
carcinoid 860 carcinoid.ConclusionsEverolimus is a treatment option for hemodialysis patients with metastatic atypical bronchial carcinoid . Based on our case report and review of literature, Everolimus does not require any dose reductions
carcinoid 1363 been reported. Here we describe the case of a hemodialysis patient with metastatic atypical bronchial carcinoid treated with everolimus.Case presentationIn February 2011, a 47-year-old white male patient underwent
carcinoid 1535 47-year-old white male patient underwent right lung lobectomy for resection of an atypical bronchial carcinoid (pT1pN2). His medical history was significant for end-stage renal disease (ESRD) secondary to focal
carcinoid 2995 conclusionsSeveral therapeutic options are available for front-line treatment of metastatic bronchial carcinoid s, including somatostatin analogues, chemotherapy, and peptide receptor radionuclide therapy [[3]].However,
carcinoid 3582 our knowledge, this is the first report of a hemodialysis patient with metastatic atypical bronchial carcinoid treated with everolimus. In the one case of a hemodialysis patient with metastatic ileal well differentiated
carcinoid 5916 patient setting. Everolimus therapy is feasible in hemodialysis patients with metastatic bronchial carcinoid . Its observed efficacy and tolerability profile are similar to those reported in patients with normal
hyperglycemia 4961 responseSafetyThiery-Vuillemin A et al. [[9]]Case reports21; 15 mgNANAGrade II asthenia, diarrhea and mucositis; grade III hyperglycemia Syrios J et al. [[10]]Case reports21; 110 mgSD; CR4 mo; 40 moWell toleratedAdytia V et al. [[11]]Single
neuroendocrine tumor 416 3/2018Publication date (collection): /2018AbstractBackgroundEverolimus was recently approved for the treatment of neuroendocrine tumor s. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not
neuroendocrine tumor 1106 hemodialysis patients.BackgroundIn two phase III trials everolimus has been shown to be active against neuroendocrine tumor s (NETs) arising from the lung [[1], [2]]. Its tolerability in lung NET patients with concomitant severe

You must be authorized to submit a review.